版本:
中国

BRIEF-Actinium selects Vector Oncology for Actimab-A Phase 2 trial

Sept 20 Actinium Pharmaceuticals Inc

* Selects Vector Oncology as its clinical research organization for Actimab A Phase 2 trial

* Actimab-A Phase 2 trial is expected to begin in 2016, will enroll 53 patients bringing total number of patients to 71 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐